Genentech and SanegeneBio struck a global licensing deal that gives Genentech rights to an RNAi program while SanegeneBio retains early development responsibilities. Genentech paid $200 million upfront and the agreement includes up to $1.5–1.7 billion in milestone payments plus tiered royalties, according to company releases. The pact pairs Genentech’s clinical and commercial capabilities with Sanegene’s RNAi chemistry and delivery platform. SanegeneBio disclosed the transaction alongside details of its broader pipeline, including multiple clinical-stage RNAi programs. Sanegene’s CEO Weimin Wang highlighted the deal as validation of their differentiated RNAi chemistry and delivery. For RNAi investors and developers, the transaction signals renewed Big Pharma appetite for liver‑targeted RNA therapeutics and foroutsourcing of later-stage development to large commercial partners.